Skip to main content
Premium Trial:

Request an Annual Quote

Susceptibility Tests Will Generate One-Third of Genomic-Diagnostics Revenue

NEW YORK, Aug. 14 - Testing for disease susceptibility will account for one-third of the total genomic-diagnostic revenues this year, according to a report released today.


The report, by health-care research firm Decision Resources, shows that revenues from sales of assays for disease-susceptibility testing, prognostics, and monitoring are projected to reach $115 million in 2002 from an estimated $71 million collected last year. If fulfilled, this forecast means that these applications will account for about 90 percent of the total genomic-diagnostics market.


Companies that currently occupy the genomics-diagnostics space include Affymetrix, Cepheid, DNA Sciences, Myriad Genetics, Nanogen, and Third Wave Technologies.


Still, "there aren't many [of these] products on the market right now," Karen O'Connor, an analyst with Decision Resources, told GenomeWeb. "These estimates have ... been based on products that have not come out to market yet."

The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to qualitative interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.